Information Provided By: 
Fly News Breaks for July 15, 2019
PSNL
Jul 15, 2019 | 07:26 EDT
Morgan Stanley analyst David Lewis initiated Personalis with an Overweight rating and $28 price target, citing his view that the company's NeXT platform is positioned to gain share as the oncology market moves toward targeted therapies. Additionally, Personalis does not have direct reimbursement risk as do peers that potentially have exposure via companion diagnostics, Lewis tells investors.
News For PSNL From the Last 2 Days
There are no results for your query PSNL
